Hemogenyx Pharmaceuticals, the biopharmaceutical group developing new therapies and treatments for blood diseases, has entered into a Master Translational Research Services Agreement with the University of Pennsylvania. The goal of the Agreement is to advance the Chimeric Antigen Receptor T-cells developed by the Company toward and through clinical trials.